Business Context and Reporting Period
electroCore, Inc. filed its Form 10-K for the fiscal year ended December 31, 2021; the filing is annual rather than a standalone fourth-quarter report. The company develops and commercializes gammaCore, a prescription, non-invasive vagus nerve stimulation therapy focused primarily on migraine and cluster headache. Revenue is concentrated in U.S. VA/DoD facilities, the United Kingdom’s National Health Service, and emerging commercial cash-pay and international distribution channels.
Key Financial Metrics
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Net sales | $5.45 million | $3.50 million | +56% |
| Gross profit | $4.07 million | $1.76 million | +$2.31 million |
| Gross margin | 75% | 50% | +25 percentage points |
| Loss from operations | $(20.04) million | $(24.75) million | Improved by $4.71 million |
| Net loss | $(17.22) million | $(23.51) million | Improved by $6.29 million |
| Net loss per share | $(0.29) | $(0.60) | Improved |
| Cash used in operating activities | $(13.63) million | $(20.05) million | Improved by $6.42 million |
| Cash, cash equivalents and marketable securities | $34.7 million | $22.6 million | +$12.1 million |
Gross margin excluding inventory charges was 76% in 2021 versus 63% in 2020. The 2021 results included a $1.42 million gain from forgiveness of the Paycheck Protection Program loan and a $0.55 million gain from termination of the Australian joint venture. The company reported an $851,000 income tax benefit, primarily related to the sale of New Jersey net operating losses.
At December 31, 2021, total assets were $42.8 million, total liabilities were $6.2 million and stockholders’ equity was $36.6 million. The company had no note payable outstanding, compared with $1.4 million of note payable in 2020. Operating lease liabilities totaled $761,000. Inventory was $5.3 million, including $3.9 million classified as noncurrent, and included an $821,000 reserve for obsolete inventory.
VA/DoD represented 59.8% of 2021 net sales, compared with 57.9% in 2020. NHS revenue represented 24.1%, compared with 29.0%. Four VA/DoD facilities accounted for 51.4% of VA/DoD sales, and two facilities individually represented more than 10% of VA/DoD revenue.
Material Changes Versus the Prior Comparable Period
- Net sales increased $2.0 million, driven by higher VA sales, international sales and U.S. commercial-channel revenue.
- Gross profit and margin increased primarily because of higher sales, favorable product mix and improved absorption of labor and overhead. The 2020 period included a $433,918 inventory charge versus $69,972 in 2021.
- Research and development expense declined 40% to $2.5 million because of lower company-sponsored clinical-trial spending, partially offset by targeted investigator-initiated trials, publications and product development.
- Selling, general and administrative expense was broadly stable at $21.6 million. Restructuring and severance charges fell to zero from $465,000.
- Operating cash burn declined to $13.6 million from $20.1 million, while financing cash inflows increased to $25.7 million from $18.9 million.
- The company issued 20.7 million common shares in July 2021 for net proceeds of approximately $18.8 million and issued additional shares in connection with legal obligations, lease termination and other settlements. Shares outstanding increased to 70.7 million at year-end from 45.6 million.
- In February 2021, gammaCore received FDA clearance for acute and preventive migraine treatment in adolescents ages 12 to 17. In September 2021, the FDA cleared label expansion for paroxysmal hemicrania and hemicrania continua in adults.
Guidance, Outlook, Commentary and Risks
Management suspended its prior full-year revenue guidance in March 2020 because of COVID-19 uncertainty and had not reinstated specific revenue guidance in the provided filing. Management expects most 2022 revenue to continue coming from VA/DoD and the United Kingdom, while investing in direct-to-consumer, cash-pay, e-commerce, telehealth, physician-dispense and international distribution initiatives. Research and development and selling, general and administrative expenses are expected to increase in 2022 as the company invests in a next-generation therapy platform and commercial expansion.
Management stated that existing cash and marketable securities are expected to fund currently planned operating and capital requirements for at least 12 months from issuance of the financial statements, but also disclosed substantial doubt regarding the company’s ability to continue as a going concern because of recurring losses and negative operating cash flow. Additional financing will likely be required beyond the current plan. A $75 million shelf registration statement became effective in January 2022.
- COVID-19 reduced access to prescribing physicians and headache patients, disrupted operations and supply chains, and continues to create uncertainty.
- The company has never been profitable and expects substantial losses and negative operating cash flow for the foreseeable future.
- Commercial success depends on payer coverage and reimbursement. GammaCore is not currently covered by Medicare and Medicaid, and pharmacy-benefit reimbursement has been limited.
- Revenue concentration in VA/DoD and NHS programs creates customer and government-policy risk.
- Expansion of cash-pay and direct-to-consumer channels is relatively new and may require significant spending without producing sufficient revenue.
- Inventory materially exceeds forecasted 2022 demand, creating potential obsolescence and future impairment risk.
- The company relies on third-party manufacturers, component suppliers, specialty pharmacies, distributors, telehealth providers and e-commerce platforms.
- Regulatory, clinical-trial, reimbursement, intellectual-property, cybersecurity, foreign-exchange and competitive risks could delay commercialization or reduce demand.
- Putative securities class actions and derivative lawsuits remain pending. The company has not accrued a loss because the probability and amount of any loss cannot currently be estimated.
- Nasdaq notified the company in December 2021 that its stock price failed to meet the $1.00 minimum bid requirement. The company had until June 20, 2022 to regain compliance.
Investor Verification Checklist
- Verify the annual financial statements and assess whether the stated cash runway remains adequate given the $13.6 million 2021 operating cash burn.
- Review the going-concern disclosure and the terms, capacity and potential dilution of future financing under the effective shelf registration statement.
- Track revenue concentration and renewal or continuation of VA/DoD and NHS reimbursement arrangements.
- Evaluate inventory aging, demand assumptions and the risk of additional obsolescence charges on the $5.3 million inventory balance.
- Monitor adoption, pricing and profitability of the new cash-pay, e-commerce and telehealth channels.
- Follow the securities and derivative litigation, including potential defense costs, settlements or judgments.
- Confirm subsequent Nasdaq listing compliance and any reverse split, equity issuance or other capital-markets actions.
- Assess whether clinical, regulatory and reimbursement developments support expansion beyond the company’s current headache indications.